Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

• Mohammad Atefi ,

  Contributed equally to this work with: Mohammad Atefi, Erika von Euw

  Affiliation Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Erika von Euw ,

  Contributed equally to this work with: Mohammad Atefi, Erika von Euw

  Affiliation Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Narsis Attar,

  Affiliation Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Charles Ng,

  Affiliation Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Connie Chu,

  Affiliation Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Deliang Guo,

  Affiliation Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Ramin Nazarian,

  Affiliation Department of Medicine, Division of Dermatology, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Bartosz Chmielowski,

  Affiliation Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• John A. Glaspy,

  Affiliations Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America, Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Begonya Comin-Anduix,

  Affiliations Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California, United States of America, Jonsson Comprehensive Cancer Center at University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Paul S. Mischel,

  Affiliations Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, United States of America, Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Roger S. Lo,

  Affiliations Department of Medicine, Division of Dermatology, University of California Los Angeles, Los Angeles, California, United States of America, Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Antoni Ribas

  * E-mail: aribas@mednet.ucla.edu

  Affiliations Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America, Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California, United States of America, Jonsson Comprehensive Cancer Center at University of California Los Angeles, Los Angeles, California, United States of America

  ⨯